OPR - Delayed Quote • USD OVID Oct 2024 7.500 call (OVID241018C00007500) Follow 0.1500 0.0000 (0.00%) At close: February 26 at 3:27 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for OVID241018C00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: OVID Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Owning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID), Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why Q3 2023 Ligand Pharmaceuticals Inc Earnings Call Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial Results
